MF59 clinical trials

Studies by the year they started

30 studies that test it; most in 2009 (5)

Who runs them

Industry 11 · Other 20

National Institute of Allergy and Infectious Diseases (NIAID) (11) · Novartis Vaccines (6) · Korea University Guro Hospital (2) · Seqirus (2) · Biomedical Advanced Research and Development Authority (2) · Novartis (2) · The University of Hong Kong (1) · Novartis Pharmaceuticals (1)

Often tested with

Tested in the same studies.

Influenza Vaccines (5) · AS03 (4) · HIV Envelope Protein gp120 (1) · Amilomotide (1) · Aluminum sulfate (1) · Aluminium sulfate (1) · Indium (1) · AS03 adjuvant (1)

Studies

Open first, then newest update. How each study uses MF59 is read from its arms, and is right about nine times in ten.

Testing it · 31

• Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older AdultsRecruitingPhase 4Korea University Guro HospitalNCT07838298Written as MF59 adjuvanted influenza vaccine
• Influenza Vaccination Strategy for Patients With Hematologic MalignancyRecruitingPhase 3Asan Medical CenterNCT07485855Written as MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)
• Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical TrialNot yet recruitingNot applicableNational Taiwan University HospitalNCT07126652Written as MF-59
• Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older AdultsCompletedPhase 4Korea University Guro HospitalNCT07805837Written as MF59-Adjuvanted Influenza Vaccine
• Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong KongCompletedPhase 4The University of Hong KongNCT03330132Written as MF 59 adjuvanted inactivated influenza vaccine (NH formulation)
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03014310Written as MF59
• A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000832Written as MF59
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03682120Written as MF59
• Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01097096Written as MF59
• Reducing the Burden of Influenza After Solid-Organ TransplantationCompletedPhase 2/3Oriol ManuelNCT03699839Written as MF59-adjuvanted influenza vaccine
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsCompletedPhase 3SeqirusNCT03314662Written as MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
• Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59CompletedPhase 2Biomedical Advanced Research and Development AuthorityNCT03497845Written as MF59 adjuvant
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of AgeCompletedPhase 3SeqirusNCT02587221Written as MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)
• Panblok H7 Vaccine Adjuvanted With AS03 or MF59CompletedPhase 2Biomedical Advanced Research and Development AuthorityNCT03283319Written as MF59
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02624219Written as MF59 adjuvant
• H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01942265Written as MF59
• gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent FemalesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00133497Written as MF-59
• H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02213354Written as MF59
• Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 MonthsCompletedPhase 2/3Novartis VaccinesNCT00996307Written as MF59-eH1N1_f
• H7N9 Mix and Match With MF59 in Healthy AdultsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01938742Written as MF59

See all 31 studies that test MF59 →